中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 621-625

Diagnosis and treatment principles of liver injury induced by antithyroid drugs

DOI: 10.12449/JCH240331
  • 1.

    School of Pharmaceutical Sciences，Southern Medical University，Guangzhou 510515，China

  • 2a.

    Department of Endocrinology and Metabolism，Zhujiang Hospital of Southern Medical University，Guangzhou 510262，China

  • 2b.

    Pharmacy Department，Zhujiang Hospital of Southern Medical University，Guangzhou 510262，China

More Information
  • Corresponding author: YANG Rui， yangrui91@163.com （ORCID： 0000-0002-3066-7709）
  • Received Date: 2023-08-08
  • Accepted Date: 2023-09-05
  • Published Date: 2024-03-20
    Abstract
  • Pharmacotherapy is the primary treatment method for hyperthyroidism. Antithyroid drugs can induce liver injury， and the diagnosis of drug-induced liver injury is mostly exclusive based on medical history collection， clinical symptoms， serum biochemistry， radiological examination， and histology. According to the severity of liver injury， drug-induced liver injury can be classified into mild， moderate， severe， and fatal degrees. Drug withdrawal may not be necessary for patients with mild liver injury， but regular monitoring of liver function is required； in severe cases， patients may develop liver failure， which may lead to a mortality rate， and early identification， timely drug withdrawal， and reasonable pharmacotherapy can help to avoid fatal consequences. The treatment principles of liver injury induced by antithyroid drugs include promoting the recovery of liver injury， preventing the severe exacerbation and chronicity of liver injury， and reducing the risk of death. Standardized medication， timely monitoring， early identification， and early treatment are important measures for the prevention and treatment of liver injury induced by antithyroid drugs.

     

    • FullText(HTML)
  • loading
    • References(32)
  • [1]
    SUZUKI N, NOH JY, HIRUMA M, et al. Analysis of antithyroid drug-induced severe liver injury in 18,558 newly diagnosed patients with Graves’ disease in Japan[J]. Thyroid, 2019, 29( 10): 1390- 1398. DOI: 10.1089/thy.2019.0045.
    [2]
    ZENG J, LUO F, LIN Z, et al. Rash and cholestatic liver injury caused by methimazole in a woman with Turner syndrome and Graves’s disease: a case report and literature review[J]. BMC Endocr Disord, 2021, 21( 1): 179. DOI: 10.1186/s12902-021-00819-1.
    [3]
    Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug⁃Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Guidelines for the diagnosis and treatment of drug-induced liver injury[J].[J]. J Clin Hepatol, 2015, 31( 11): 1752- 1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31( 11): 1752- 1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [4]
    Professional Committee of Prevention and Treatment of Pharmaceutical Liver Injury of China Medical Biotechnology Association, Pharmaceutical Hepatology Group of Liver Disease Branch of Chinese Medical Association. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version)[J]. Chin J Gastroenterol, 2022, 27( 6): 341- 375. DOI: 10.3760/cma.j.cn501113-20230419-00176.

    中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤诊治指南(2023年版)[J]. 胃肠病学, 2022, 27( 6): 341- 375. DOI: 10.3760/cma.j.cn501113-20230419-00176.
    [5]
    YU W, WU N, LI L, et al. Side effects of PTU and MMI in the treatment of hyperthyroidism: a systematic review and meta-analysis[J]. Endocr Pract, 2020, 26( 2): 207- 217. DOI: 10.4158/EP-2019-0221.
    [6]
    CARRION AF, CZUL F, AROSEMENA LR, et al. Propylthiouracil-induced acute liver failure: role of liver transplantation[J]. Int J Endocrinol, 2010, 2010: 910636. DOI: 10.1155/2010/910636.
    [7]
    MIKHAIL NE. Methimazole-induced cholestatic jaundice[J]. South Med J, 2004, 97( 2): 178- 182. DOI: 10.1111/j.1572-0241.2001.03469.x.
    [8]
    COOPER DS. Antithyroid drugs[J]. N Engl J Med, 2005, 352( 9): 905- 917. DOI: 10.1056/NEJMra042972.
    [9]
    HEIDARI R, NIKNAHAD H, JAMSHIDZADEH A, et al. Factors affecting drug-induced liver injury: antithyroid drugs as instances[J]. Clin Mol Hepatol, 2014, 20( 3): 237- 248. DOI: 10.1155/2010/910636.
    [10]
    MIZUTANI T, YOSHIDA K, MURAKAMI M, et al. Evidence for the involvement of N-methylthiourea, a ring cleavage metabolite, in the hepatotoxicity of methimazole in glutathione-depleted mice: structure-toxicity and metabolic studies[J]. Chem Res Toxicol, 2000, 13( 3): 170- 176. DOI: 10.1021/tx990155o.
    [11]
    HEIDARI R, BABAEI H, EGHBAL M. Mechanisms of methimazole cytotoxicity in isolated rat hepatocytes[J]. Drug Chem Toxicol, 2013, 36( 4): 403- 411. DOI: 10.3109/01480545.2012.749272.
    [12]
    SUN J, ZHAO F, LIN B, et al. Gut microbiota participates in antithyroid drug induced liver injury through the lipopolysaccharide related signaling pathway[J]. Front Pharmacol, 2020, 11: 598170. DOI: 10.3389/fphar.2020.598170.
    [13]
    CLARKE JI, DEAR JW, ANTOINE DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety-false dawn or new horizon?[J]. Expert Opin Drug Saf, 2016, 15( 5): 625- 634. DOI: 10.1517/14740338.2016.1160057.
    [14]
    DEAR JW, CLARKE JI, FRANCIS B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies[J]. Lancet Gastroenterol Hepatol, 2018, 3( 2): 104- 113. DOI: 10.1016/S2468-1253(17)30266-2.
    [15]
    GALLELLI L, STALTARI O, PALLERIA C, et al. Hepatotoxicity induced by methimazole in a previously healthy patient[J]. Curr Drug Saf, 2009, 4( 3): 204- 206. DOI: 10.2174/157488609789006912.
    [16]
    LI L, JIANG W, WANG J. Clinical analysis of 275 cases of acute drug-induced liver disease[J]. Front Med China, 2007, 1( 1): 58- 61. DOI: 10.1056/NEJMra052270.
    [17]
    FORD R, SCHWARTZ L, DANCEY J, et al. US Food and Drug Administration. Center for Drug Evaluation and Research(CDER), Center for Biologics Evaluation and Research(CBER). Guidance for industry: drug-induced liver injury-premarketing clinical evaluation[J]. Eur J Cancer, 2009, 45( 2): 268- 274.
    [18]
    de ALMEIDA R, MCCALMON S, CABANDUGAMA PK. Clinical review and update on the management of thyroid storm[J]. Mo Med, 2022, 119( 4): 366- 371.
    [19]
    WAN YM, WU JF, LI YH, et al. Prednisone is not beneficial for the treatment of severe drug-induced liver injury: An observational study(STROBE compliant)[J]. Medicine(Baltimore), 2019, 98( 26): e15886. DOI: 10.1097/MD.0000000000015886.
    [20]
    MA JGJ, LAMMERT C. Characterization of steroid therapy for drug-induced liver injury[J]. Gastroenterology, 2020, 158( 6): S-1304. DOI: 10.1016/S0016-5085(20)33922-6.
    [21]
    WANG JB, HUANG A, WANG Y, et al. Corticosteroid plus glycyrrhizin therapy for chronic drug- or herb-induced liver injury achieves biochemical and histological improvements: a randomised open-label trial[J]. Aliment Pharmacol Ther, 2022, 55( 10): 1297- 1310. DOI: 10.1111/apt.16902.
    [22]
    HEIDARI R, BABAEI H, ROSHANGAR L, et al. Effects of enzyme induction and/or glutathione depletion on methimazole-induced hepatotoxicity in mice and the protective role of N-acetylcysteine[J]. Adv Pharm Bull, 2014, 4( 1): 21- 28. DOI: 10.5681/apb.2014.004.
    [23]
    SQUIRES RH, DHAWAN A, ALONSO E, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial[J]. Hepatology, 2013, 57( 4): 1542- 1549. DOI: 10.1002/hep.26001.
    [24]
    YANG J, ZHONG J, ZHOU LZ, et al. Sudden onset agranulocytosis and hepatotoxicity after taking methimazole[J]. Intern Med, 2012, 51( 16): 2189- 2192. DOI: 10.2169/internalmedicine.51.7845.
    [25]
    WANG Y, WANG Z, GAO M, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: A phase II trial[J]. Liver Int, 2019, 39( 11): 2102- 2111. DOI: 10.1111/liv.14204.
    [26]
    LI WX, RAO Z, WU T, et al. Clinical effect of magnesium isoglycyrrhizinate in the treatment of drug-induced liver injury induced by methimazole[J]. Clin Ration Drug Use, 2023, 16( 16): 69- 71. DOI: 10.15887/j.cnki.13-1389/r.2023.16.019.

    李文旋, 饶志, 武涛, 等. 异甘草酸镁治疗甲巯咪唑致药物性肝损伤的临床效果[J]. 临床合理用药, 2023, 16( 16): 69- 71. DOI: 10.15887/j.cnki.13-1389/r.2023.16.019.
    [27]
    WANG Y, LAI R, ZONG P, et al. Bicyclol for the treatment of drug-induced liver injury: a propensity score matching analysis using a nationwide inpatient database[J]. J Int Med Res, 2021, 49( 4): 3000605211005945. DOI: 10.1177/03000605211005945.
    [28]
    TANG J, GU J, CHU N, et al. Efficacy and safety of bicyclol for treating patients with idiosyncratic acute drug-induced liver injury: A multicenter, randomized, phase II trial[J]. Liver Int, 2022, 42( 8): 1803- 1813. DOI: 10.1111/liv.15290.
    [29]
    APAYDıN T, ELBASAN O, YAVUZ DG. Preoperative plasmapheresis experience in Graves’ disease patients with anti-thyroid drug-induced hepatotoxicity[J]. Transfus Apher Sci, 2020, 59( 5): 102826. DOI: 10.1016/j.transci.2020.102826.
    [30]
    ZHANG Q, GUAN Y, XIANG T, et al. Combination of molecular adsorbent recirculating system and radioiodine for the treatment of concurrent hyperthyroidism and severe liver dysfunction: a retrospective cohort study[J]. Endocr Pract, 2017, 23( 2): 141- 148. DOI: 10.4158/EP161417.OR.
    [31]
    ZHENG M, CUI S, ZHANG W, et al. Graves’ disease overlapping with chronic hepatitis B and methimazole-induced liver injury and autoimmune hepatitis: a case report[J]. BMC Gastroenterol, 2022, 22( 1): 59. DOI: 10.1186/s12876-022-02133-z.
    [32]
    BENIĆ MS, NEŽIĆ L, VUJIĆ-ALEKSIĆ V, et al. Novel therapies for the treatment of drug-induced liver injury: a systematic review[J]. Front Pharmacol, 2021, 12: 785790. DOI: 10.3389/fphar.2021.785790.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (383) PDF downloads(118) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return